Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Rh-YBS** is an experimental oral colonic submucosa-targeted drug-probiotic co-delivery system for ulcerative colitis. It co-encapsulates the small molecule rhein and live *Bacillus subtilis* within yeast cell wall microparticles. The carrier is designed to target colonic microfold cells and deliver the payload to the colonic submucosa, where rhein promotes *B. subtilis* colonization. In a dextran sulfate sodium-induced mouse model of ulcerative colitis, the system increased calcitonin gene-related peptide-associated signaling, promoted goblet-cell mucus secretion, and supported mucosal repair and prevention of colitis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40344311/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rh-YBS.